

Would your therapeutic be reimbursed?



'Reducing your risk, increasing your value'


www.genechron.com

Would your therapeutic be reimbursed?


If you aren't addressing this question now, then your pipeline's NPV risk profile is too high

Genechron is providing solutions for the short, medium and long-term issues that are prohibiting:

- Better ROI's in R&D
- Other companies licensing your innovations
- Reimbursement agencies agreeing for healthcare systems to prescribe your therapeutics




Our products provide detailed (relative and quantitative) *in vivo* measurements informing you whether your therapeutics in development also induce:



- Liver damage (DILI/Drug induced hepatotoxicity)
- Cardiac toxicity
- Skeletal muscle toxicity
- Inflammation and mitochondrial damage

or


- Stimulate liver repair
- Correct cardiac comorbidities
- Correct skeletal muscle comorbidities
- Reduce inflammation and correct underlying mechanisms of disease



Working **exclusively** with microRNA that have been reproducibly and independently confirmed to be:

- Linked with the tissue and diseases that affect them
- Proven in animal models used for preclinical development
- Validated in human disease

**Our solutions complement your existing avenues of
Research, development and clinical validation**






Following reception of serum samples from your study animals or clinical trial subjects and microRNA analysis by Genechron you will make:

- 'Fail early, fail frequent' decisions during early development of the therapeutic
- Correlations with all other measured parameters to assess dosage requirements and impacts on toxicity vs primary morbidity vs comorbidity
- Demonstrations to partners, clients and agencies that your therapeutic addresses the market needs of polypharmacy reduction and comorbidity correction
- Clear stratification and rapid adaptation of your clinical testing to prevent company value loss as a result of clinical failures

Our products during therapeutic development



Product	Question answered
Tox	Drug induced liver toxicity
Tox+	Long term liver toxicity and damage
Mechatox	Mechanism of toxicity
Comorbitox	Induction of cytotoxicity
Comorbitype	Comorbidity impact
Inflammatox	Impact on inflammation and cytotoxicity
Cardiomech	Definition and understanding of mechanism of cardiac correction
Musclemech	Definition and understanding of mechanism of skeletal muscle correction

All of the above measurements can be performed on murine and human serum samples

MicroRNA levels can be measured under two diverse approaches, depending on your needs and under diverse regulatory standards.

Relative measurement

Obtain a 'yes or no' answer on the impact of your therapeutic as compared to your controls

Absolute measurements

Obtain detailed insight of number of microRNA molecules per millilitre of serum to integrate in additional biometric parameters to standardise for ROA, strain, species, dose, weight, gender, stage and precise pathophysiology of the disease, blood parameters and additional factors that you integrate into your testing design, such as functionality.

These measurements can also be performed under GLP conditions (upon request)

“MicroRNA-122 as a biomarker.... has the potential **to bridge results in in vitro experiments to in vivo animal models and human samples using the same assay**, and to link findings from clinical studies in determining the relevance of in vitro models being developed for the study of drug-induced liver injury.” R. Kia et al, *MicroRNA-122: A Novel Hepatocyte-Enriched in vitro Marker of Drug-Induced Cellular Toxicity Toxicological Sciences*, 144(1), 2015, 173–185

We believe this potential applies to microRNA122 which we have measurement products for, and for our other microRNA combination measurements that address comorbidities.

Genechron is a company able to provide advanced and enhanced microRNA analysis and NGS services that adds value and reduces the risks of your pipeline from preclinical through clinical development, into market release and follow up.

www.genechron.com

Contact: jonathan.dando@genechron.com or info@genechron.com

